[BostonCard]

These biomarker data correlated with LY-CoV555's positive impact on the prespecified endpoint of COVID-19-related hospitalization or ER visit. This endpoint occurred in 1.7 percent (5/302) of LY-CoV555 patients, pooled across dose groups, as compared to 6 percent (9/150) of placebo patients, which corresponds to a 72 percent risk reduction in this limited population.

The numbers are small and the confidence interval is wide, but if you used the point estimate, you would need to treat 23 patients with COVID-19 to prevent one COVID-19-related hospitalization on ER visit.  Whether it is worth it might depend on whether most of those are hospitalizations or ER visits.

BC

[BostonCard]

These biomarker data correlated with LY-CoV555's positive impact on the prespecified endpoint of COVID-19-related hospitalization or ER visit. This endpoint occurred in 1.7 percent (5/302) of LY-CoV555 patients, pooled across dose groups, as compared to 6 percent (9/150) of placebo patients, which corresponds to a 72 percent risk reduction in this limited population.

The numbers are small and the confidence interval is wide, but if you used the point estimate, you would need to treat 23 patients with COVID-19 to prevent one COVID-19-related hospitalization on ER visit.  Whether it is worth it might depend on whether most of those are hospitalizations or ER visits.

BC